Microbiota-directed therapies for atopic dermatitis currently lack consistent human clinical evidence
Microbiome therapies for eczema still lack strong evidence
This narrative review examines microbiota-directed therapies including probiotics, postbiotics, and microbial metabolites for atopic dermati…
A new review finds that microbiome-based treatments for atopic dermatitis are promising but backed by limited human data.
FDA Approves Anzupgo (delgocitinib) for Moderate to Severe Chronic Hand Eczema
FDA approves new cream Anzupgo for chronic hand eczema in adults.
The FDA approved Anzupgo (delgocitinib) topical cream for moderate to severe chronic hand eczema in adults with inadequate response to topic…
The FDA approved Anzupgo (delgocitinib) cream for moderate to severe chronic hand eczema in adults who haven't improved with steroid creams.…
FDA Approves Cibinqo (abrocitinib) for Refractory Moderate-to-Severe Atopic Dermatitis
FDA approves new pill Cibinqo for hard-to-treat eczema in adults and teens.
The FDA approved Cibinqo (abrocitinib) for adults and pediatric patients 12 years and older with refractory moderate-to-severe atopic dermat…
The FDA approved Cibinqo (abrocitinib) for moderate-to-severe eczema in people 12 and older when other treatments fail. This new once-daily …
Mogamulizumab monotherapy achieves 41.2% overall response rate in patients with cutaneous T-cell lymphomas
Mogamulizumab Shows Meaningful Response in Cutaneous T-cell Lymphoma
This systematic review and meta-analysis of 453 patients evaluated mogamulizumab for Cutaneous T-cell Lymphomas, including Mycosis Fungoides…
New data shows mogamulizumab may be more effective for patients with Sézary Syndrome and blood involvement in certain skin cancers.
Long-term Safety Profile of Dupilumab in Adults with Moderate to Severe Atopic Dermatitis
Long-term dupilumab use shows low infection rates in skin conditions
A five-year open-label extension study confirms that dupilumab maintains a favorable safety profile regarding infection rates in adult patie…
A five-year study of adults with moderate to severe atopic dermatitis suggests that long-term dupilumab treatment is not linked to increased…
IO102-IO103 plus pembrolizumab improves progression-free survival in advanced melanoma patients
Trial shows combination therapy may extend time before melanoma progresses
This Phase III randomized controlled trial of 407 patients with untreated advanced melanoma evaluated IO102-IO103 (85 μg) combined with pemb…
A new clinical trial suggests that combining two specific drugs may help patients with advanced melanoma stay stable for longer periods.
Sentinel lymph node biopsy shows 9% positivity rate in patients with desmoplastic melanoma
Sentinel Lymph Node Biopsy Shows Specific Results for Desmoplastic Melanoma
This meta-analysis of 1671 patients evaluates sentinel lymph node biopsy (SLNB) for desmoplastic melanoma. The pooled SLN positivity rate is…
A review of data shows that sentinel lymph node biopsy has a 9% positivity rate in patients with desmoplastic melanoma.
Motivation-informed digital reminders do not improve task completion compared to standard wording in melanoma trial
Standard Digital Reminders Work Well for Melanoma Monitoring Tasks
This randomized study within a trial (SWAT) of 260 participants in a melanoma surveillance program found that motivation-informed digital re…
New research shows that standard digital reminders are just as effective as motivation-based ones for helping patients complete melanoma mon…
Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysis
Upadacitinib Shows Highest Efficacy for Moderate to Severe Atopic Dermatitis
A systematic review and network meta-analysis of 9 RCTs (4261 adults) found upadacitinib 30 mg had the highest efficacy for EASI-75, IGA-AD …
A review of data from over 4,000 patients suggests upadacitinib may be the most effective oral treatment among several JAK inhibitors for se…
EV-associated proteins and miRNAs provide high diagnostic accuracy for Lichen Planus and Oral Lichen Planus
New markers show promise for diagnosing Lichen Planus cases
This meta-analysis evaluates the diagnostic utility of extracellular vesicle (EV) associated miRNA and protein biomarkers in patients with L…
Specific proteins and genetic markers could help doctors more accurately identify and track the progression of Lichen Planus.
FDA Approves Skyrizi (risankizumab) for Ulcerative Colitis in Adults
FDA approves Skyrizi for adults with moderate to severe ulcerative colitis.
The FDA approved Skyrizi (risankizumab) for moderately to severely active ulcerative colitis in adults. The recommended induction dosage is …
The FDA approved Skyrizi (risankizumab) for adults with moderate to severe ulcerative colitis. It is given as an IV infusion at first, then …
FDA Approves Skyrizi (risankizumab) for Ulcerative Colitis in Adults
FDA approves Skyrizi for ulcerative colitis, a new treatment option.
The FDA approved Skyrizi (risankizumab) for moderately to severely active ulcerative colitis in adults. The approval adds to existing indica…
The FDA approved Skyrizi (risankizumab) for adults with moderate to severe ulcerative colitis. It is given as an IV infusion at first, then …